Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers. The company is also developing MCLA-117 that is in Phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a Phase I clinical trial for treating metastatic colorectal cancer. In addition, its preclinical development stage bispecific antibody candidates include MCLA-145, which is being developed in collaboration with Incyte Corporation; and other preclinical candidates in various stages of development. Merus N.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MRUS
CUSIPN/A
Phone31-30-253-8800
Debt
Debt-to-Equity RatioN/A
Current Ratio10.05
Quick Ratio10.05
Price-To-Earnings
Trailing P/E Ratio-5.47
Forward P/E Ratio-6.36
P/E GrowthN/A
Sales & Book Value
Annual Sales$15.36 million
Price / Sales34.37
Cash FlowN/A
Price / CashN/A
Book Value$2.79 per share
Price / Book8.36
Profitability
EPS (Most Recent Fiscal Year)($4.29)
Net Income$-82,610,000.00
Net Margins-530.70%
Return on Equity-91.14%
Return on Assets-28.35%
Miscellaneous
Employees51
Outstanding Shares22,630,000
Market Cap$554.08
Merus (NASDAQ:MRUS) Frequently Asked Questions
What is Merus' stock symbol?
Merus trades on the NASDAQ under the ticker symbol "MRUS."
How were Merus' earnings last quarter?
Merus NV (NASDAQ:MRUS) posted its earnings results on Thursday, April, 26th. The biotechnology company reported ($0.86) earnings per share for the quarter. The biotechnology company earned $4.49 million during the quarter. Merus had a negative return on equity of 91.14% and a negative net margin of 530.70%. View Merus' Earnings History.
When is Merus' next earnings date?
What price target have analysts set for MRUS?
3 Wall Street analysts have issued 12-month price objectives for Merus' shares. Their predictions range from $28.00 to $32.00. On average, they expect Merus' share price to reach $30.00 in the next year. This suggests a possible upside of 28.6% from the stock's current price. View Analyst Ratings for Merus.
What is the consensus analysts' recommendation for Merus?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Merus' key competitors?
Some companies that are related to Merus include ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Arena Pharmaceuticals (ARNA), Akorn (AKRX), Zogenix (ZGNX), Myokardia (MYOK), Puma Biotechnology (PBYI), Prestige Brands (PBH), Insmed (INSM), Phibro Animal Health (PAHC), Cambrex (CBM), Mallinckrodt (MNK), AnaptysBio (ANAB), Aimmune Therapeutics (AIMT) and PTC Therapeutics (PTCT).
Who are Merus' key executives?
Merus' management team includes the folowing people:
- Dr. Ton Logtenberg Ph.D., Co-Founder, CEO & Exec. Director (Age 60)
- Dr. Hennie Hoogenboom Ph.D., Co-Founder and Scientific Advisor
- Mr. John J. Crowley, CFO & Exec. VP (Age 44)
- Mr. John de Kruif Ph.D., CTO & Sr. VP
- Mr. Mark Throsby Ph.D., Chief Scientific Officer & Exec. VP (Age 51)
When did Merus IPO?
(MRUS) raised $64 million in an IPO on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.
Has Merus been receiving favorable news coverage?
Media headlines about MRUS stock have been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Merus earned a coverage optimism score of 0.15 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 45.46 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of Merus?
Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Merus' stock price today?
One share of MRUS stock can currently be purchased for approximately $23.33.
How big of a company is Merus?
Merus has a market capitalization of $554.08 million and generates $15.36 million in revenue each year. The biotechnology company earns $-82,610,000.00 in net income (profit) each year or ($4.29) on an earnings per share basis. Merus employs 51 workers across the globe.
How can I contact Merus?
Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-30-253-8800 or via email at [email protected]
MarketBeat Community Rating for Merus (NASDAQ MRUS)
MarketBeat's community ratings are surveys of what our community members think about Merus and other stocks. Vote "Outperform" if you believe MRUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
